<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319667</url>
  </required_header>
  <id_info>
    <org_study_id>EFC12522</org_study_id>
    <secondary_id>2017-002238-21</secondary_id>
    <secondary_id>U1111-1194-2121</secondary_id>
    <nct_id>NCT03319667</nct_id>
  </id_info>
  <brief_title>Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant</brief_title>
  <acronym>IMROZ</acronym>
  <official_title>A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate the benefit of isatuximab (I) in combination with bortezomib (V), lenalidomide
      (R) and dexamethasone (d) in the prolongation of progression free survival (PFS) as compared
      with bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple
      myeloma (NDMM) not eligible for transplant.

      Secondary Objectives:

        -  To evaluate in both randomized arms: very good partial response (VGPR) or better rate as
           defined by the International Myeloma Working Group (IMWG) criteria, complete response
           (CR) rate per IMWG criteria, minimal residual disease (MRD) negativity rate in patients
           with CR or VGPR, time to progression (TTP), PFS in MRD negative patients, duration of
           response (DOR), PFS on next line of therapy (PFS2), overall survival (OS), overall
           response rate (ORR) (including crossover arm) per IMWG criteria (including crossover
           arm), safety (including crossover arm), and to assess disease-specific and generic
           health-related quality of life (HRQL)

        -  To determine the pharmacokinetic (PK) profile of isatuximab in combination with
           bortezomib, lenalidomide, and dexamethasone (excluding crossover arm)

        -  To evaluate the immunogenicity of isatuximab in patients receiving isatuximab (including
           crossover arm)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for each patient will include a screening period of up to 4 weeks,
      an induction period of 24 weeks (4 cycles with a duration of 42 ± 4 days), a continuous
      treatment period and a crossover period (when applicable). The cycle duration is 28 ± 4 days
      during the continuous treatment and crossover periods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel and crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to approximately 60 months after the first patient in (FPI) or scheduled assessment</time_frame>
    <description>PFS defined as the time from the date of randomization to the date of first documentation of progression disease (PD) as determined by the independent review committee (IRC) or the date of death from any cause, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Very good partial response (VGPR) or better rate</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Proportion of patients with CR and VGPR as assessed by the IRC using the IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CR)</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Proportion of patients with CR as assessed by the IRC using the IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) negativity rate</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Proportion of patients with CR and VGPR and for whom MRD measurement is negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Proportion of patients with best overall response (BOR) recorded as CR, VGPR, or partial response (PR) as assessed by the IRC using the IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Defined as the time from randomization to date of first documentation of PD as assessed by the IRC using the IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Defined as the time from date of first IRC determined response to date of first IRC PD or death, whichever occurs first for patients achieving CR, VGPR, or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS on next line of therapy (PFS2)</measure>
    <time_frame>At 4 years after cutoff for primary PFS analysis</time_frame>
    <description>Defined as the time from randomization to second objective PD, or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in MRD negative patients</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Defined as the time from the date of randomization to the date of first documentation of PD or the date of death from any cause, whichever comes first in MRD negative patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>At 4 years after cutoff for primary PFS analysis</time_frame>
    <description>Defined as the time from the date of randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 30 days after end of treatment (EOT) visit</time_frame>
    <description>Treatment-emergent adverse events/serious adverse events (TEAEs/SAEs) including infusion associated reactions (IARs), second primary malignancies, laboratory parameters, vital signs, weight, ECOG PS, and findings from physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Ctrough</measure>
    <time_frame>Cycle 1 Day 8/Day 15/Day 29 (pre-dose) and Day 1 (pre-dose) of Cycle 2, 3, 4, 5, 6, 7, 8, 9 and 10 (Duration of each cycle for Cycles 1-4: 6 weeks; Duration of each cycle for Cycles 5-10: 4 weeks)</time_frame>
    <description>Isatuximab: Pre-dose plasma isatuximab concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC</measure>
    <time_frame>Cycle 1 Day 1 to Day 29</time_frame>
    <description>Isatuximab: Cumulative area under the plasma isatuximab concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: CL</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 10 Day 1 (Duration of each cycle for Cycles 1-4: 6 weeks; Duration of each cycle for Cycles 5-10: 4 weeks)</time_frame>
    <description>Isatuximab: Clearance (CL) for linear non-specific elimination pathway</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Levels of isatuximab anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome (PRO): QLQ-C30</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO: QLQ-MY20</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Disease- and treatment-related quality of life will be assessed using the EORTC myeloma module (QLQ-MY20) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO: EQ-5D-5L</measure>
    <time_frame>Up to approximately 60 months after the FPI or scheduled assessment</time_frame>
    <description>Health state utility and health status will be assessed using the European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone
Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib/Lenalidomide/Dexamethasone = VRd arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone
Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab SAR650984</intervention_name>
    <description>Pharmaceutical form: Solution for infusion
Route of administration: Intravenous (IV)</description>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_label>Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Pharmaceutical form: Lyophilized powder for injection
Route of administration: Intravenous/Subcutaneous</description>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_label>Bortezomib/Lenalidomide/Dexamethasone = VRd arm</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Pharmaceutical form: Capsules
Route of administration: Oral</description>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_label>Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm</arm_group_label>
    <arm_group_label>Bortezomib/Lenalidomide/Dexamethasone = VRd arm</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Pharmaceutical form: Tablets, ampoules or vials for injection
Route of administration: Oral/Intravenous</description>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_label>Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm</arm_group_label>
    <arm_group_label>Bortezomib/Lenalidomide/Dexamethasone = VRd arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen (paracetamol) or equivalent</intervention_name>
    <description>Pharmaceutical form: Tablets
Route of administration: Oral</description>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_label>Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine or equivalent</intervention_name>
    <description>Pharmaceutical form: Solution for injection
Route of administration: Intravenous</description>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_label>Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine or equivalent</intervention_name>
    <description>Pharmaceutical form: Solution for injection
Route of administration: Intravenous</description>
    <arm_group_label>Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm</arm_group_label>
    <arm_group_label>Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Symptomatic multiple myeloma (IMWG criteria).

          -  Newly diagnosed multiple myeloma not eligible for transplant due to age (≥ 65 years)
             or patients &lt; 65 years with comorbidities impacting possibility of transplant or
             patient's refusal of transplant.

          -  Evidence of measurable disease.

          -  Written informed consent.

        Exclusion criteria:

          -  Age &lt; 18 years.

          -  Prior treatment for multiple myeloma.

          -  Asymptomatic multiple myeloma.

          -  Any other prior or ongoing disease/health conditions incompatible with the study
             objectives.

          -  Organ function values not met.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ( PS) &gt; 2.

          -  Hypersensitivity to the study medications.

          -  Pregnant, breastfeeding, or woman of child bearing potential unwilling to use
             recommended contraception methods.

          -  Male participants who disagree to follow the study contraceptive counseling.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 0360005</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360004</name>
      <address>
        <city>Heidelberg West</city>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360006</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360008</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360007</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360001</name>
      <address>
        <city>Waratah</city>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360002</name>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560002</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030002</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030007</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030004</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030003</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030006</name>
      <address>
        <city>Plzen</city>
        <zip>30599</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030005</name>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030001</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2080002</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2080003</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2080004</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500011</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500008</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500012</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500006</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500005</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500010</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000001</name>
      <address>
        <city>Athens</city>
        <zip>11538</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3000002</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800005</name>
      <address>
        <city>Ancona</city>
        <zip>60032</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920004</name>
      <address>
        <city>Higashiibaraki-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920008</name>
      <address>
        <city>Konan-Ku, Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920007</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920001</name>
      <address>
        <city>Shibuya-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920006</name>
      <address>
        <city>Sunto-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920010</name>
      <address>
        <city>Yamagata-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4400002</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4400001</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5540003</name>
      <address>
        <city>Hamilton</city>
        <zip>3200</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200002</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200001</name>
      <address>
        <city>Lisboa</city>
        <zip>1070</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200005</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200003</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430001</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430002</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240004</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7520004</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7520001</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580003</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580002</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580001</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920007</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920001</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920002</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920004</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920003</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920005</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920008</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

